SK Capital Closes Acquisition of Catalent’s Blow-Fill-Seal  Sterile CDMO Business and Changes Name to Woodstock  Sterile Solutions; Announces CEO Paul Josephs

New York, March 31, 2021 – Funds managed by SK Capital Partners LP, a private  investment firm focused on the specialty materials, chemicals and  pharmaceuticals sectors, completed the previously announced acquisition of the  Blow-Fill-Seal (“BFS”) Sterile Contract Development and Manufacturing business  from Catalent Pharma Solutions, LLC. The business has been renamed  Woodstock Sterile Solutions (“Woodstock” or the “Company ”), reflecting its  long-standing rich heritage in the Woodstock, Illinois community.

Woodstock is a leading BFS sterile contract development and manufacturing  organization (CDMO) that operates out of a single site in Woodstock, Illinois,  focusing on complex clinical to commercial stage formulation and manufacturing.  The Company supports a global, blue-chip customer base with a broad array of  products that leverage its BFS sterile manufacturing capabilities and formulation  competency in complex chemistries including small molecule, biologics,  macromolecules, and potent compounds.

Woodstock has also announced the appointment of Paul Josephs as the  Company’s Chief Executive Officer, effective immediately. Mr. Josephs comes to  Woodstock having most recently served as Head of Contract Development &  Manufacturing & Global Business Development at Mylan, a global generic and  specialty pharmaceuticals company. Previously, Mr. Josephs held several  leadership roles at DPT Laboratories.

Aaron Davenport, a Managing Director of SK Capital, stated, “We are excited to  launch Woodstock Sterile Solutions as an independent company, building on its  decades of experience in serving commercial and development customers. We  are delighted that Paul Josephs is joining to lead the very capable Woodstock  team. Paul is a CDMO industry veteran who brings sterile production experience  and contemporary leadership skills to ensure an environment committed to  operational excellence, customer delight, innovation, and a partnership driven  approach for Woodstock’s customers, suppliers, and employees.”

“I am truly honored and excited to lead an organization with the heritage and  potential of Woodstock,” Mr. Josephs stated. “I look forward to partnering with

SK Capital, the executive team and all Woodstock associates to leverage the  Company’s unique sterile manufacturing capabilities, strong market position and  exceptional talent in executing our growth strategy. The BFS and sterile  manufacturing markets are significant growth areas in our industry and together  we have a great opportunity to positively impact the lives of countless patients,  domestically and abroad.”

Debt financing was provided by Cerberus Business Finance, LLC. Mizuho  Securities served as financial advisor and Kirkland & Ellis LLP acted as legal  counsel to SK Capital. RBC Capital Markets served as financial advisor and Paul,  Weiss, Rifkind, Wharton & Garrison LLP acted as legal counsel to Catalent.

About SK Capital

SK Capital is a private investment firm with a disciplined focus on the specialty  materials, chemicals and pharmaceuticals sectors. The firm seeks to build strong  and growing businesses that create substantial long-term economic value. SK  Capital utilizes its industry, operating and investment experience to identify  opportunities to transform businesses into higher performing organizations with  improved strategic positioning, growth and profitability as well as lower  operating risk. SK Capital’s portfolio of businesses generates revenues of  approximately $11 billion annually, employs more than 15,000 people globally  and operates 135 plants in 28 countries. The firm currently has greater than $5 billion of assets under management. For more information, please visit  www.skcapitalpartners.com.